


Enzymatic Therapy

NATURAL MEDICINES®

November 21, 2003



Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 810
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir or Madam::

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

PRODUCT NAME	STATEMENT	INGREDIENT(S)
AM/PM Menopause Formula™*	Easy Answers is a 3-Stage system for every woman's life! Each system includes a hormone-free, natural hormone balancer, a stage-specific multivitamin, targeted bone health support and relief for the uncomfortable symptoms of PMS, perimenopause and menopause.*	<u>AM Formula:</u> Green Tea Leaf Extract, Panax Ginseng Root Phytosome™, Black Cohosh Root and Rhizome Extract <u>PM Formula:</u> Valerian Root Extract, Hops Flower Extract, L-Theanine, Black Cohosh Root and Rhizome Extract


I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert Doster
Robert Doster
Title: Senior Vice President of Scientific Affairs

Date: 11/21/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

A handwritten signature in black ink, reading "Michael P. Devereux". The signature is fluid and cursive, with the first name "Michael" being the most prominent.

Michael P. Devereux
Chief Financial Officer